GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
GAiT has been reorganizing for the next stage in its growth and development. More ambitious goals necessitated internal reviews, strategic decisions, and system restructuring. Thankfully our operations are now again normalized and we shall now be more communicative with members.
"I think we're ready - I would even say we're waiting," @EMA_News Exec Director Emer Cooke told me when I asked her if the agency is ready for the coming wave of ATMPs. Looking forward to sharing the full #CGMED21 keynote address with attendees next week! https://meetingonthemed.com/
Longtime #ISSCR member and President of the Korean Society for Stem Cell Research (KSSCR), Jiwhan Song shares the focus of his research, what led him to become a scientist, and what he does in his free time! #MemberMonday #MemberSpotlight http://ow.ly/cU2t50E3uKI
#ISCT2021 program now available!
Find session descriptions at
6 Plenaries • 6 Tracks • 48+ Sessions
ISCT 2021 Program
Session descriptions now available!
Thanks to Maxime Feyeux @TreefrogTx for interviewing GAiT about its efforts to clarify the roadmap for iPSC translation. The interview will appear as a Podcast in the 'In The Stem Cell Jungle' series shortly.
In the Stem Cell Jungle I Webcast by Maxime Feyeux
The idea of having laid-back conversations with academic and industry leaders in the field of stem cells and cell ...
Happy International Women's Day. Half of GAiT's Directors are women: Jacqueline Barry (CGTCatapult), Susan Solomon (NYSCF) and Annelise Bennaceur Griscelli (INSERM).
To avail of an extra three months of GAiT industry membership at no extra cost, remember to pay your annual industry subscription this week.
Pluripotent Stem Cell Manufacturing Expert Panels - developing action plans to deal with common challenges http://gait.global/expert-panels-2019-agenda/ We look forward to the follow up meeting later this year.
Industry membership subscriptions are now due. Pay before 10th March and extend your company's membership an extra three months at no extra cost.
Pluripotent Stem Cell Manufacturing Expert Panels - developing action plans to deal with common challenges http://www.gait.global/expert-panels-2019-agenda/ We look forward to the follow up meeting later this year.